AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of its president in the country.

The probe conducted by China regulators, which reportedly centers on allegations that AstraZeneca employees improperly imported cancer medications like Enhertu and Imjudo from Hong Kong into ...

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...

AstraZeneca (NASDAQ:AZN) has changed several key management positions in its China business as the Anglo-Swedish drugmaker looks to boost its sales following the recent detention of its President ...

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...

The probe conducted by China regulators, which reportedly centers on allegations that AstraZeneca employees improperly imported cancer medications like Enhertu and Imjudo from Hong Kong into ...

Jan 17 (Reuters) - AstraZeneca (AZN.L), opens new tab has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and ...